Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab

摘要: 1002 Background: Current methods used to select HER2 positive patients with metastatic breast cancer for treatment trastuzumab are semi-quantitative and yield response rates of less than fifty percent. Using a novel assay quantitate total homodimer levels, we examined the relationship between these measurements clinical outcomes in cohort trastuzumab-treated patients, previously assessed as IHC 3+ or FISH+ overexpression amplification. Methods: The VeraTag was measure expression (H2T) homodimers (H2D) 106 formalin-fixed, paraffin-embedded primary tumor specimens. test trend, multivariate Cox proportional hazards, Kaplan-Meier analyses, results were correlated objective response, time-to-progression (TTP), overall survival following trastuzumab-containing treatment. Results: Higher levels H2T (p= 0.008) H2D 0.001) higher probability respo...